Skip to main content
Nature Communications logoLink to Nature Communications
. 2026 Feb 5;17:1388. doi: 10.1038/s41467-026-69268-5

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Shuo Li 1,2,3, Zorawar S Noor 4, Weihua Zeng 1, Mary L Stackpole 1,2,3, Xiaohui Ni 5, Yonggang Zhou 1, Zuyang Yuan 1, Wing Hung Wong 6,7, Vatche G Agopian 8, Steven M Dubinett 1,4,9,10, Frank Alber 3,11, Wenyuan Li 1,3,, Edward B Garon 4,, Xianghong Jasmine Zhou 1,3,
PMCID: PMC12877192  PMID: 41644545

Correction to: Nature Communications 10.1038/s41467-021-24457-2, published online 7 July 2021

In the version of the article initially published, the Competing interests section was incomplete and has now been expanded in the HTML and PDF versions of the article to: “X.J.Z., W.L., and W.H.W. are co-founders of EarlyDiagnostics. X.J.Z and W.H.W serve on the Board of Directors for EarlyDiagnostics. X.J.Z. has an executive leadership position at EarlyDiagnostics. S.M.D. is a scientific advisor to EarlyDiagnostics. X.N., S.L., and M.L.S. are employees of EarlyDiagnostics. S.L., W.Z., M.L.S., X.N., Y.Z., S.M.D. have stock options with EarlyDiagnostics. X.J.Z., W.L., W.H.W., and F.A. are stockholders of EarlyDiagnostics. W.Z., Y.G., and W.L. are consultants for EarlyDiagnostics. X.J.Z., S.L. and W.L. are inventors on a patent application submitted by the Regents of the University of California and licensed to EarlyDiagnostics (Patent No. US20210125683A1). The other authors have no competing interests to declare.”

Contributor Information

Wenyuan Li, Email: WenyuanLi@mednet.ucla.edu.

Edward B. Garon, Email: EGaron@mednet.ucla.edu

Xianghong Jasmine Zhou, Email: XJZhou@mednet.ucla.edu.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES